Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations
about
Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits.In vivo activity of amphotericin B lipid complex in immunocompromised mice against fluconazole-resistant or fluconazole-susceptible Candida tropicalis.In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effectComparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbitsIn vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolatesDetermination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization.Incidence of bloodstream infections in small bowel transplant recipients receiving selective decontamination of the digestive tract: A single-center experienceBlad-Containing Oligomer Fungicidal Activity on Human Pathogenic Yeasts. From the Outside to the Inside of the Target Cell.Liposomal nystatin in patients with invasive aspergillosis refractory to or intolerant of amphotericin B.Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole.A sensitive amphotericin B immunoassay for pharmacokinetic and distribution studies.In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolatesApplication of Various Types of Liposomes in Drug Delivery Systems.Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B.
P2860
Q31058690-6AE43E9A-B7AD-442E-8F7F-A515DE489246Q33979132-79F3C7E8-8A58-461B-8A43-01F3D733DD37Q33980705-67098C6E-7CAA-47FB-920F-9BBD6ACD1330Q33980861-66044656-3E32-483F-AE12-C4A1A4E0F0AFQ34229980-D29E8221-93EB-448B-88C7-9E7DB31839CCQ34452652-DB5B37F1-AFB1-417C-A1ED-7256B2C52435Q35745822-4711267B-B0AE-4342-92CF-3180BBAFE661Q36815096-5FB2994A-5F42-4921-A78B-58D3991A1750Q37438608-598C4F14-8E6F-4793-810D-A5CCBC62A817Q37625418-0C1D6D70-8A7A-48D1-9827-2B30CE45F2F4Q39470726-EBE77FA0-6149-4925-A95E-2A428298D262Q39473015-A00EE123-4BB2-4FAA-BE76-F6CA5613ECA4Q39650951-0988EC6E-D80E-4B90-A5D0-9C031C4D19E5Q42352352-53BA8EE3-A83F-4435-9A52-2ECC5A33F6EBQ42391942-0F325C69-F2C1-4C39-9AF1-F869CF7C427E
P2860
Comparison of in vitro antifungal activities of free and liposome-encapsulated nystatin with those of four amphotericin B formulations
description
1998 nî lūn-bûn
@nan
1998 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հունիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Comparison of in vitro antifun ...... ur amphotericin B formulations
@ast
Comparison of in vitro antifun ...... ur amphotericin B formulations
@en
type
label
Comparison of in vitro antifun ...... ur amphotericin B formulations
@ast
Comparison of in vitro antifun ...... ur amphotericin B formulations
@en
prefLabel
Comparison of in vitro antifun ...... ur amphotericin B formulations
@ast
Comparison of in vitro antifun ...... ur amphotericin B formulations
@en
P2093
P2860
P356
P1476
Comparison of in vitro antifun ...... ur amphotericin B formulations
@en
P2093
D W Warnock
E M Johnson
J O Ojwang
T L Wallace
P2860
P304
P356
10.1128/AAC.42.6.1412
P407
P577
1998-06-01T00:00:00Z